Hepatitis C Treatment Snapshots: Daclatasvir

Hepatitis C Treatment Snapshots: Daclatasvir

For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
Patent Situation of The Key Product For Treatment of Hepatitis C: SOFOSBUVIR – WHO working paper, updated 2015
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Updated Generic Sofosbuvir Availability and Price in India 15 June 2015
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
20 YEARS AFTER THE TRIPS AGREEMENT, U.S. GOVERNMENT SCORES MASSIVE VICTORY FOR BIG PHARMA IN TPP DEAL
Asia Pacific Situational Updates on Generic DAAs – June 2017
IAC a community group in Indonesia demanding national food and drugs authority to expedite registration process of DAA medicines in Indonesia